Novo Integrated Sciences, Inc. (NVOS)

USD 0.0

(0.0%)

EBITDA Summary of Novo Integrated Sciences, Inc.

  • Novo Integrated Sciences, Inc.'s latest annual EBITDA in 2023 was -5.84 Million USD , up 11.94% from previous year.
  • Novo Integrated Sciences, Inc.'s latest quarterly EBITDA in 2024 Q1 was -3.39 Million USD , down -34.85% from previous quarter.
  • Novo Integrated Sciences, Inc. reported an annual EBITDA of -22.47 Million USD in 2022, down -157.72% from previous year.
  • Novo Integrated Sciences, Inc. reported an annual EBITDA of -2.58 Million USD in 2021, up 15.8% from previous year.
  • Novo Integrated Sciences, Inc. reported a quarterly EBITDA of -3.39 Million USD for 2024 Q1, down -34.85% from previous quarter.
  • Novo Integrated Sciences, Inc. reported a quarterly EBITDA of -1.27 Million USD for 2024 Q2, up 67.79% from previous quarter.

Annual EBITDA Chart of Novo Integrated Sciences, Inc. (2023 - 2004)

Historical Annual EBITDA of Novo Integrated Sciences, Inc. (2023 - 2004)

Year EBITDA EBITDA Growth
2023 -5.84 Million USD 11.94%
2022 -22.47 Million USD -157.72%
2021 -2.58 Million USD 15.8%
2020 -2.78 Million USD -1262.79%
2019 130.44 Thousand USD 85.38%
2018 -1.47 Million USD -13192.11%
2017 -16.69 Thousand USD 93.25%
2016 -164.88 Thousand USD 58.84%
2015 -277.77 Thousand USD -359.2%
2014 -87.23 Thousand USD 71.54%
2013 -306.51 Thousand USD 62.35%
2012 -989.9 Thousand USD 63.34%
2011 -2.22 Million USD 4.5%
2010 -2.32 Million USD -17.8%
2009 -1.97 Million USD -108.76%
2008 -945.39 Thousand USD 61.78%
2007 -2.47 Million USD -69.36%
2006 -1.46 Million USD -36.92%
2005 -1.06 Million USD -409.84%
2004 -209.22 Thousand USD 0.0%

Peer EBITDA Comparison of Novo Integrated Sciences, Inc.

Name EBITDA EBITDA Difference
American Oncology Network, Inc. -39.35 Million USD 85.136%
ATI Physical Therapy, Inc. 82.86 Million USD 107.058%
Assure Holdings Corp. -19.82 Million USD 70.495%
Panamera Holdings Corporation -7.12 Million USD 17.859%